- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
David Newman, GlaxoSmithKline
S
David Newman
Senior Product Director, Tykerb, GlaxoSmithKline
NOTED FOR: Launch of oncology treatment Tykerb
EXCEEDED RESULTS: Treated 5,500 patients
On what motivates him to succeed:
We think we have it tough. But that's nothing compared to fighting breast cancer. These women help us put our work in perspective, and give us a sense of mission to not necessarily sell Tykerb, but instead make sure every patient gets its benefit of efficacy.
David Newman
In a therapeutic area like oncology, you have a chance to make a real difference. That focus is what keeps me motivated day in and day out.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
